Loading stock data…
IGC Pharma, Inc. (IGC)
$0.27+0.01 (+3.04%)
Market ClosedLast close Jun 29
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IGC Pharma, Inc. in the Healthcare sector is trading at $0.27 with a market capitalization of $30M. Wall Street consensus targets $4.25 (2 analysts), implying a +1468.3% move over the next 12 months. The stock is currently near its 52-week low of $0.24, remaining 15.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 20 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +1468.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 20) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $317,000↓ | $350,000↑ | $191,000↓ | $328,000↓ | $330,000 |
| Gross Profit | $55,000↑ | $44,000↓ | $99,000↓ | $154,000 | $154,000 |
| Operating Income | -$2.46M↑ | -$2.94M↓ | -$2.90M↓ | -$1.91M↓ | -$1.41M |
| Net Income | -$2.40M↓ | -$726,000↑ | -$1.82M↓ | -$1.60M↓ | -$1.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-106.98%
Volume
Today's trading volume
515,155
Recent News
IGC Pharma, New to The Street launch 12-part national media partnership
New to The Street announced a strategic 12-part media partnership with IGC Pharma (IGC). The multi-faceted campaign is designed to elevate IGC Pharma’s visibility across institutional and retail investor audiences through a coordinated media strategy that includes long-form television interviews, national TV commercial distribution, high-impact outdoor billboard placements, and curated accredited investor events in key financial markets. Through this initiative, IGC Pharma will be featured acros
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
IGC Pharma expands Phase 2 CALMA trial with new clinical site
IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease dementia. VIN operates clinical research programs embedded within established private neurology practices, providing access to well-characterized patient populations while maintaining continuity of clinical care. IGC Pharma believes this practice-integrated mo